Companies › Keymed Biosciences Co.Ltd
9 active drug programs in 17 registered trials: 8 Phase 1, 8 Phase 2, 1 Phase 3; Oncology, Immunology, Hematology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CM310 IL-4 receptor (IL-4Rα) monoclonal antibody | IL4R | Phase 3 | Atopic Dermatitis | – |
| CM336 BCMA/CD3 bispecific antibody | BCMA, CD3E, TNFRSF17 | Phase 2 | Primary Light-Chain Amyloidosis; Multiple Myeloma; Autoimmune Cytopenia; Autoimmune Bullous Disease | Dec 2026 |
| CM512 injection | – | Phase 2 | Atopic Dermatitis; Chronic Spontaneous Urticaria (CSU); Asthma; Atopic Dermatitis (AD) | Jan 2027 |
| CM338 | – | Phase 2 | IgA Nephropathy | Jun 2027 |
| CM313(SC) injection | – | Phase 2 | Primary Immune Thrombocytopenia; Platelet Transfusion Refractoriness | Nov 2027 |
| CM383 | – | Phase 1 | Healthy; Alzheimer Disease | Dec 2026 |
| CM350 anti-GPC3 antibody | GPC3 | Phase 1 | Advanced Solid Tumor | Apr 2027 |
| CM518D1 | – | Phase 1 | Advanced Solid Tumors | Dec 2028 |
| CM559 | – | Phase 1 | Healthy Subjects | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06594146 | CM313(SC) injection | Phase 2 | Primary Immune Thrombocytopenia | Hematology | Dec 2025 |
| NCT07175506 | CM559 | Phase 1 | Healthy Subjects | Other | Jun 2026 |
| NCT07292688 | CM383 | Phase 1 | Healthy | Other | Jul 2026 |
| NCT06947980 | CM512 injection | Phase 2 | Atopic Dermatitis | Immunology | Jul 2026 |
| NCT06495229 | CM310 | Phase 3 | Atopic Dermatitis | Immunology | Aug 2026 |
| NCT05299424 | CM336 | Phase 1 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT06619613 | CM383 | Phase 1 | Alzheimer Disease | Neurology | Dec 2026 |
| NCT06900010 | CM336 | Phase 2 | Autoimmune Bullous Disease | Immunology | Jan 2027 |
| NCT07166211 | CM512 injection | Phase 2 | Chronic Spontaneous Urticaria (CSU) | Immunology | Jan 2027 |
| NCT05263960 | CM350 | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2027 |
| NCT05775042 | CM338 | Phase 2 | IgA Nephropathy | Genitourinary | Jun 2027 |
| NCT07011524 | CM512 injection | Phase 2 | Asthma | Respiratory | Jul 2027 |
| NCT06792019 | CM313(SC) injection | Phase 1 | Platelet Transfusion Refractoriness | Hematology | Nov 2027 |
| NCT07175493 | CM336 | Phase 1 | Autoimmune Cytopenia | Hematology | Nov 2027 |
| NCT07230483 | CM512 injection | Phase 2 | Atopic Dermatitis (AD) | Immunology | Dec 2027 |
| NCT07019779 | CM518D1 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2028 |
| NCT07039578 | CM336 | Phase 2 | Primary Light-Chain Amyloidosis | Metabolic and endocrine | Jul 2029 |
Genrix (Shanghai) Biopharmaceutical Suzhou Zelgen Biopharmaceuticals argenx Miltenyi Biomedicine Ipsen
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.